Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

7.280 -0.660 (-8.31%)
Streaming Delayed Price Updated: 10:16 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
FDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy Treatment ↗
The FDA released  
Via Benzinga
News headline image
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. 
Via Benzinga
News headline image
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗
 
Via Benzinga
News headline image
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023 ↗
 
Via Benzinga
News headline image
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share. 
Via Benzinga
News headline image
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.